Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
04/2003
04/17/2003WO2003030615A2 Biocidal mixture of 2-propenal-releasing polymer and isothiazolones
04/17/2003WO2003030613A2 Methods of treating liver fibrosis and hepatitis c virus infection
04/17/2003WO2003011883A3 Process for the preparation of l-ribavirin
04/17/2003WO2002094863A3 INTERFERON-α INDUCED GENE
04/17/2003WO2002085930A3 Immunomodulating agents from parasitic worms and method for isolation thereof
04/17/2003WO2002085928A3 Modified cyclosporine which can be used as a pro-drug and use thereof
04/17/2003WO2002076426A3 Intravaginal drug delivery devices for the administration of an antimicrobial agent
04/17/2003WO2002072622A3 Vaccine antigens against infection by chlamydia trachomatis
04/17/2003WO2002069943A3 Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies
04/17/2003WO2002061070A3 Environmentally regulated genes, involved in the virulence of streptococcus suis
04/17/2003WO2002051237A9 Helicobacter proteins, nucleic acids and uses thereof
04/17/2003WO2002050289A9 Methods for the production of multimeric proteins, and related compositions
04/17/2003WO2002032865A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
04/17/2003WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
04/17/2003WO2001000635A3 Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
04/17/2003WO1999067238A3 Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
04/17/2003WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands
04/17/2003US20030074691 Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein
04/17/2003US20030074676 I0nduction of preferential immunoglobulin in mammal; obtain mammal, immunize with tumor necrosis factor, monitor expression of immunoglobulin in milk
04/17/2003US20030074142 Coincidence detection programmed media and system
04/17/2003US20030073826 Crystaline clindamycin free base
04/17/2003US20030073825 Azalide antibiotic compositions
04/17/2003US20030073727 Central nervous system disorders
04/17/2003US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease
04/17/2003US20030073699 Compounds and methods to treat cardiac failure and other disorders
04/17/2003US20030073696 Oxazolidinone photoaffinity probes
04/17/2003US20030073692 Anticancer agents; viricides; Alzheimer's diseases
04/17/2003US20030073686 Anticarcinogenic agents
04/17/2003US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents
04/17/2003US20030073682 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
04/17/2003US20030073651 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
04/17/2003US20030073648 Crystaline clindamycin free base
04/17/2003US20030073647 Crystaline clindamycin free base
04/17/2003US20030073625 Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides
04/17/2003US20030073611 Detoxification of cells, tissues
04/17/2003US20030073223 For use in vaccines
04/17/2003US20030073167 DNA encoding SNORF36 receptors
04/17/2003US20030073148 Antibodies binding to human airway trypsin-like protease and methods for utilizing the same
04/17/2003US20030073095 Nucleotide sequences coding bacterial protein for use in the treatment and prevention of bacterial infections
04/17/2003US20030073080 Genetically engineered viral nucleotide sequences for use as tool in gene therapy and vaccine development
04/17/2003US20030072822 Methods for treating disorders using plant extracts
04/17/2003US20030072814 Topical pharmaceutical composition for the treatment of warts
04/17/2003US20030072800 Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation
04/17/2003US20030072771 Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142
04/17/2003US20030072769 Used in the manufacture of vaccines, therapy, prophylaxis, drug screening
04/17/2003US20030072766 Comprising antiserum raised against a flagellaless Campylobacter strain for prophylaxis of Campylobacter colonisation in animals
04/17/2003US20030072765 For therapy and prophylaxis of bacterial infections
04/17/2003US20030072764 Mucosal boosting following parenteral priming
04/17/2003US20030072762 For enhancing Fc receptor-mediated antigen presentation, vaccines
04/17/2003US20030072753 Virus-like particles for the induction of autoantibodies
04/17/2003US20030072742 Enhancement of immune response using targeting molecules
04/17/2003US20030072736 Human tumor necrosis factor receptor TR16
04/17/2003CA2473970A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
04/17/2003CA2471968A1 Immunostimulatory nucleic acids and use thereof
04/17/2003CA2464662A1 Modulation of the expression of genes dependent on stat-1
04/17/2003CA2463496A1 Method of obtaining an extract of ginger
04/17/2003CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003CA2463198A1 Pyrrolidinone derivatives
04/17/2003CA2462886A1 Flashmelt oral dosage formulation
04/17/2003CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003CA2462876A1 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003CA2462291A1 Methods and compositions for treating dermal lesions
04/17/2003CA2461291A1 Inhibition of exoprotein production using aromatic compositions
04/17/2003CA2461145A1 Live attenuated salmonella strains for producing vaccines
04/17/2003CA2461064A1 Inhibition of stat-1
04/17/2003CA2460690A1 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
04/17/2003CA2460625A1 Structural and cytoskeleton-associated proteins
04/17/2003CA2460476A1 Protein modification and maintenance molecules
04/17/2003CA2460341A1 Methods of treating liver fibrosis and hepatitis c virus infection
04/17/2003CA2458392A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
04/16/2003WO2003032915A2 Viral inhibition by n-docosanol
04/16/2003EP1302541A1 Receptor protein specifically recognizing bacterial dna
04/16/2003EP1302475A1 Sugar chain-containing carbosilane dendrimer compounds, process for producing the same and verotoxin neutralizers and antiviral agents
04/16/2003EP1302468A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds
04/16/2003EP1302205A1 Controlled release formulations of macrolide citrate salts
04/16/2003EP1302201A1 Pharmaceutical composition improved in peroral absorbability
04/16/2003EP1302115A1 Use of cystathionine
04/16/2003EP1301797A2 Antimicrobial agent
04/16/2003EP1301637A2 Dna vaccines encoding hiv accessory proteins
04/16/2003EP1301616A2 Bicistronic influenza viruses comprising two genes in tandem
04/16/2003EP1301615A2 Adenovirus vectors comprising introns
04/16/2003EP1301614A1 Codon-optimized papilloma virus sequences
04/16/2003EP1301606A1 Expression system
04/16/2003EP1301605A2 Nk cells activating receptors and their therapeutic and diagnostic uses
04/16/2003EP1301602A2 Fh-binding protein of streptococcus pneumoniae
04/16/2003EP1301598A2 Cell cycle proteins and mitosis-associated molecules
04/16/2003EP1301595A2 G-protein coupled receptors
04/16/2003EP1301539A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
04/16/2003EP1301535A2 G-protein coupled receptors
04/16/2003EP1301530A2 Multiple antigenic peptides immunogenic against streptococcus pneumoniae
04/16/2003EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301527A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies
04/16/2003EP1301519A2 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
04/16/2003EP1301507A2 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
1 ... 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 ... 1798